Regeneron Says EMA Committee Supports Extended Libtayo Dosing
The EMA's CHMP adopted a positive opinion recommending approval of an alternative dosing schedule for Libtayo, Regeneron said. The available report does not specify the dosing interval.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.